GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MEX:GILD) » Definitions » E10

Gilead Sciences (MEX:GILD) E10 : MXN116.65 (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Gilead Sciences E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Gilead Sciences's adjusted earnings per share data for the three months ended in Sep. 2024 was MXN19.690. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is MXN116.65 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Gilead Sciences's average E10 Growth Rate was -8.80% per year. During the past 3 years, the average E10 Growth Rate was 9.50% per year. During the past 5 years, the average E10 Growth Rate was 6.70% per year. During the past 10 years, the average E10 Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Gilead Sciences was 85.40% per year. The lowest was 4.50% per year. And the median was 31.65% per year.

As of today (2024-12-13), Gilead Sciences's current stock price is MXN1850.00. Gilead Sciences's E10 for the quarter that ended in Sep. 2024 was MXN116.65. Gilead Sciences's Shiller PE Ratio of today is 15.86.

During the past 13 years, the highest Shiller PE Ratio of Gilead Sciences was 68.21. The lowest was 9.93. And the median was 13.75.


Gilead Sciences E10 Historical Data

The historical data trend for Gilead Sciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences E10 Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.28 98.25 118.03 117.74 111.62

Gilead Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 113.27 111.62 102.58 113.35 116.65

Competitive Comparison of Gilead Sciences's E10

For the Drug Manufacturers - General subindustry, Gilead Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Shiller PE Ratio falls into.



Gilead Sciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=19.69/133.0289*133.0289
=19.690

Current CPI (Sep. 2024) = 133.0289.

Gilead Sciences Quarterly Data

per share eps CPI Adj_EPS
201412 32.155 99.070 43.177
201503 42.076 99.621 56.186
201506 45.815 100.684 60.533
201509 51.708 100.392 68.518
201512 54.680 99.792 72.892
201603 43.551 100.470 57.664
201606 47.713 101.688 62.418
201609 48.145 101.861 62.877
201612 48.244 101.863 63.005
201703 38.599 102.862 49.919
201706 42.117 103.349 54.212
201709 37.385 104.136 47.758
201712 -58.133 104.011 -74.351
201803 21.256 105.290 26.856
201806 27.313 106.317 34.175
201809 29.928 106.507 37.381
201812 0.045 105.998 0.056
201903 29.873 107.251 37.053
201906 28.237 108.070 34.759
201909 -18.163 108.329 -22.304
201912 39.983 108.420 49.058
202003 28.607 108.902 34.945
202006 -61.398 108.767 -75.093
202009 6.406 109.815 7.760
202012 24.467 109.897 29.617
202103 28.004 111.754 33.335
202106 24.086 114.631 27.952
202109 42.152 115.734 48.451
202112 6.154 117.630 6.960
202203 0.398 121.301 0.436
202206 18.307 125.017 19.480
202209 28.563 125.227 30.343
202212 25.345 125.222 26.925
202303 14.420 127.348 15.063
202306 14.229 128.729 14.704
202309 30.135 129.860 30.870
202312 19.351 129.419 19.891
202403 -55.431 131.776 -55.958
202406 23.633 132.554 23.718
202409 19.690 133.029 19.690

Add all the adjusted EPS together and divide 10 will get our e10.


Gilead Sciences  (MEX:GILD) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Gilead Sciences's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=1850.00/116.65
=15.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Gilead Sciences was 68.21. The lowest was 9.93. And the median was 13.75.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Gilead Sciences E10 Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).